1 Title:

Clinical Relevance and Applicability of the 2022 World Health 2

- Organization Classification of Childhood B Lymphoblastic 3
- Leukemia in the Context of MRD-Directed Therapy 4
- 5

Running Title: 6

7 Clinical Relevance of WHO5 Classification in B-ALL

8 **Authors:**

- Sweta Rajpal^{1,2}, Gaurav Chatterjee^{1,2}, Prasanna Bhanshe¹, Vishram Terse¹, Swapnali Joshi¹, Shruti Chaudhary¹, Dhanalaxmi Shetty^{4,2}, Purvi Mohanty^{4,2}, Chetan Dhamne^{3,2}, Prashant Tembhare^{1,2}, Shyam Srinivasan^{3,2}, Akanksha Chichra^{3,2}, Nirmalya Roy Malik^{3,2}, Shripad Banavali^{3,2}, Sumeet Gujral^{1,2}, Gaurav Narula^{3,2}, PG Subramanian^{1,2}, Nikhil Patkar^{1,2}* 9 10
- 11
- 12
- 13
- 14 **Type of Article:**
- **Full Article** 15

16 **Affiliations:**

- 17 ¹ Department of Haematopathology, ACTREC, Tata Memorial Centre, Navi Mumbai, India
- 18 ²Homi Bhabha National Institute (HBNI), Mumbai, India
- 19 ³Pediatric Haematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, India
- 20 ⁴Dept of Cytogenetics, ACTREC, Tata Memorial Centre, Navi Mumbai, India
- 21 *Corresponding Author

22 **Correspondence:**

- 23 Dr Nikhil Patkar MD.DNB
- 24 Clinician Scientist & Professor
- 25 Wellcome Trust - DBT Senior Fellow
- Department of Hematopathology, CCE Building, Advanced Centre for Treatment Research and 26
- 27 Education in Cancer, Tata Memorial Centre, Kharghar, Maharashtra, India, Pin: 410210
- 28 Email: nvpatkar@gmail.com
- 29 Phone: +91-22-27405000
- 30
- 31 Word Count: Article: 3426, No of Figures: 4; No of Tables: 4; References: 21, Supplementary Files:1
- 32 **Competing Interests:** The authors have no conflict of interest to declare
- 33 **Keywords:** B Cell Precursor ALL, RNA sequencing, MRD Directed Therapy

34 Abstract

35 WHO5-2022 classification of B-lymphoblastic leukemia (B-ALL) incorporates several novel entities requiring high-throughput sequencing for their accurate characterization. 36 37 The clinical relevance of this classification in the context of contemporary MRD-directed 38 therapy is unclear. We analyzed 533 pediatric B-ALL uniformly treated with ICiCLe-ALL-14 39 protocol as defined by WHO2016 and reclassified them as per WHO5-2022 using targeted sequencing, FISH, and cytogenetics. Subtype-defining genetic abnormalities were identified in 40 81.2% of the cohort as per the WHO5 classification. Among the new subtypes, PAX5^{alt}, MEF2D-41 42 r, and BCR::ABL1-like(ABL-class) were associated with an inferior 2-year event-free survival 43 (EFS) of 39.1% (p<0.0001), 53.8% (p=0.024) and 60.6% (p=0.043), respectively. We developed 44 a 3-tier genetic risk stratification model incorporating 15 genetic subtypes and the IKZF1 45 deletion. Children with standard, intermediate, and high genetic risk demonstrated 2-year EFS of 46 92.6%, 71.0%, and 50.7% (p<0.0001), and 2-year overall survival of 94.3%, 81.9%, and 71.6% 47 (p<0.0001), respectively. Genetic risk further identified heterogeneous outcomes among ICiCLe 48 risk groups (p < 0.0001). Standard genetic risk was associated with superior OS and EFS 49 irrespective of MRD status. We demonstrate the applicability of the WHO5 classification in 50 routine practice and create a general framework for incorporating the WHO5 classification in 51 risk-adapted therapy for childhood B-ALL.

52 Introduction

In the last few decades, successful adoption of risk-directed therapy has resulted in
remarkably improved pediatric B-lymphoblastic leukemia/lymphoma (B-ALL) outcomes.
Assessment of therapeutic response by detecting and quantitating measurable residual disease
(MRD) forms the cornerstone of contemporary risk-adapted protocols.

57 The underlying biology of the B-ALL subtype, which includes abnormalities of 58 chromosome number such as high hyperdiploid as well as chimeric gene fusions such as 59 *ETV6::RUNX1*, are clinically relevant even in the context of MRD-directed therapies.¹ 60 Contemporary protocols have thus adopted an integrated approach incorporating both baseline 61 genetics and MRD as an optimal strategy for risk-directed therapy.^{1,2}

62 In the last decade, we have significantly advanced our understanding of B-ALL biology 63 due to progress in genome sequencing technologies such as whole genome and transcriptome 64 sequencing. These seminal studies have led to the identification of novel biological subgroups of B-ALL.^{3,4} The WHO5 and ICC classifications have incorporated several of these new subtypes, 65 such as TCF3::HLF1, PAX5 alteration (PAX5^{alt}), PAX5 P80R, DUX4-rearrangement (DUX4-r), 66 MEF2D-r, ZNF384-r, NUTM1-r, ETV6::RUNX1-like, IG::MYC.^{5,6} Recently, Jeha and colleagues 67 have shown the clinical significance of the new subtypes of B-ALL in the context of the MRD-68 directed St. Jude Total Therapy Study 16 protocol. ⁷ It is important to validate and incorporate 69 these genomics data into clinical practice for prognostication and targeted therapy.^{7,8} 70

A major challenge in detecting the WHO5-recognised subtypes of B-ALL in routine practice is the heterogenous biology of B-ALL, which requires integration of copy number alterations, fusions involving multiple genes with various partners, and somatic mutations to

74 comprehensively detect all subtypes. For diagnosis of these new entities, legacy workflows like 75 fluorescent in situ hybridization (FISH), multiplexed PCR, and multiplex ligation-dependent 76 probe amplification (MLPA) require multiple rounds of reflexive testing that would result in 77 time delay. Furthermore, PCR-based tests require knowledge of both partners involved in the 78 fusion, which is not always feasible, especially with the novel described entities.

79 Whole transcriptome sequencing (WTS) has been proposed as a one-stop solution for this 80 problem; however, the clinical translation of WTS in practice is challenging due to the resource-81 intensive nature and turn-around time of WTS, especially if RNA-sequencing results are to 82 impact therapeutic decisions. We have previously validated NARASIMHA, a lab-developed, 83 cost-effective modular targeted RNA-sequencing assay to detect chimeric gene fusions with 84 knowledge of only one partner gene involved in the fusion (for, e.g., ABL1). We hypothesized 85 that a combination of targeted DNA and RNA sequencing, with an initial screen based on legacy 86 techniques, could detect all the entities described in the WHO5 classification of B-ALL.

Here, we present the clinical utility of this approach in detecting WHO5 subtypes in a
large, uniformly treated cohort of pediatric B-ALL. We further describe the clinical relevance of
such an approach in predicting outcomes in the context of MRD-directed therapy in childhood BALL.

91 Methods

92 Diagnostic Evaluation of B-ALL

93 Diagnosis: A total of 533 newly diagnosed pediatric B-ALL, aged 1-15 years, enrolled in the ICiCLe-ALL-14 trial (Clinical Trials Registry-India number, CTRI/2015/12/006,434), from 94 95 whom peripheral blood or bone marrow samples were received for molecular testing between 96 January 2019 to March 2022, were included in this study (overview in Supplementary Figure 1). 97 B-ALL diagnosis was made using a 10-12 color, 5-tube multi-color flow cytometry (MFC) panel as per WHO2016 criteria, as described elsewhere.⁹ Also, ploidy status was determined using the 98 FxCycle Violet-dye-based MFC method.¹⁰ Informed consent was taken from the legal gurdians 99 100 while enrolling in the ICiCLe-ALL-14 trial (Clinical Trials Registry-India number, 101 CTRI/2015/12/006,434) for participation and data sharing including publication. Institutional 102 Ethics Committee of ACTREC, Tata Memorial Centre gave ethical approval for this work (IEC 103 III – 900924).

104 Cytogenetics Work-up: FISH was performed using locus-specific identifier (LSI) probes 105 for BCR::ABL1 (Zytovision, Bremerhaven, Germany), TCF3::PBX1 (CytoTest, Rockville, 106 USA), ETV6::RUNX1, and KMT2A-r (Abbott, Green Oaks, USA). Hyperdiploid B-ALL was 107 diagnosed using centromeric FISH probes for chromosomes 4, 10, and 17 (Zytovision, 108 Bremerhaven, Germany). SureFISH 7p12.2 IKZF1 (Agilent Dako, USA) probe was used to 109 detect partial/whole IKZF1 gene deletions. Ploidy analysis was also performed on Giemsa-110 stained metaphases obtained from overnight cultured BMA/peripheral blood cells to determine 111 the modal chromosome number. Analysis was carried out under a fluorescence microscope

(Olympus BX61) using GenASIs software (Applied Spectral Imaging, Israel), and 200 intact
 interphase nuclei were evaluated by two independent co-observers as previously described.¹¹

Polymerase Chain Reaction based screening: Common translocations (BCR::ABL1
(E13/14A2 and E1A2), ETV6::RUNX1, TCF3::PBX1 and KMT2A::AFF1) were screened using
real-time PCR. IKZF1 deletions were detected using fragment length analysis.^{12,13}

Next Generation Sequencing: Targeted RNA sequencing was performed in 392 patients
(73.5%) who were negative for common translocations (Supplementary Figure 1, Supplementary
Table 1). Patients with negative RNA sequencing (n=124) were subjected to targeted DNA
sequencing. The details of these assays and bioinformatics analysis can be seen in supplementary
data.

122 Risk stratification and treatment protocol: Patients were stratified according to the 123 ICiCLe-ALL-14 risk stratification detailed in the supplementary data. These patients were treated according to the ICiCLe-ALL-14 risk-adapted protocol.¹⁴ Briefly, patients underwent 124 125 four intensive treatment blocks (induction, consolidation, interim maintenance, delayed 126 intensification) followed by 96 weeks of maintenance, varying treatment intensity according to 127 risk group. The first randomization explored the toxicity impact of a shorter induction schedule 128 of prednisolone (3 vs 5 weeks) in young, non-high-risk B-ALL patients. The second 129 randomization assessed the survival benefits of replacing doxorubicin with mitoxantrone during 130 delayed intensification across all patients (Supplementary Figure 2). Only fifteen patients 131 underwent an allogeneic Hematopoietic stem cell transplant. Post-induction (PI) and post-132 consolidation (PC) MRD assessments were performed using our previously validated highly sensitive MFC assay.¹⁵ 133

134 *Classification according to WHO 2016 and WHO 2022:* The pediatric B-ALL cases were
135 assigned to defined genetic categories as per the WHO 2016 (revised 4th edition), and WHO
136 2022 (5th edition) Classification of Tumours of Haematopoietic and Lymphoid Tissues
137 integrating DNA ploidy by MFC, FISH, chromosomal counting, screening PCR, NARASIMHA
138 and targeted DNA sequencing.¹⁶

139 Clinical Endpoints and Statistical Analysis: Overall survival (OS) was calculated from 140 the diagnosis date to either the last follow-up date or death with censoring at the last contact. 141 Event-free survival (EFS) was defined from diagnosis to events like death, relapse, or refractory 142 status, also censored at the last contact. Chi-square or Fisher's exact test (two-sided) in MedCalc 143 (version 14.8.1) assessed the association between categorical variables such as MRD positivity 144 and genetic subgroups. The impact of genetic subgroups on EFS and OS was analyzed using 145 Kaplan-Meier curves, generated on Python3 (version 3.12.0), and compared using the log-rank test. We stratified genetic risk into standard (SGR), intermediate (IGR), and high risk (HGR) 146 147 based on genetic predictors of outcome and published literature for rare variants. This 148 stratification was correlated with PI MRD and ICiCLe risk groups. Kaplan-Meier curves for 149 these subgroups were produced using MedCalc (version 14.8.1). Multivariate analysis was 150 performed using the Cox proportional-hazards regression analysis.

151 **Results**

152 *Clinical, laboratory, and risk stratification characteristics of patients enrolled:* Our final 153 analysis included 533 children with B-ALL with a male-to-female ratio of 1.99:1 and a median age of 5 years. According to the NCI risk stratification, most patients were classified as standard 154 155 risk (SR, 67.2%). However, with the final ICiCLe risk stratification, the majority (57.4%) were 156 categorized as high risk (HiR), followed by SR (22.9%) and intermediate risk (IR, 19.7%). 157 Nearly one-third of patients (32.2%, out of 519 assessed) were detected to harbor measurable 158 residual disease (defined as MRD $\geq 0.01\%$) at the PI timepoint. Similarly, 9.8% (out of 244 159 assessed) were positive at the PC timepoint. A summary of clinical, laboratory, and genetic 160 characteristics, as well as MRD responses, can be seen in Table 1.

161 Characterization of Genetic Subgroups and their Correlations: Through the integration 162 of conventional PCR, targeted RNA sequencing, cytogenetics, and immunophenotyping, we identified 13 distinct genetic subgroups within our cohort (Table 2). PAX5 ^{alt} (24, 4.5%), 163 164 BCR::ABL1-like (23, 4.3%), DUX4-r (12, 2.3%), MEF2D-r (13, 2.4%), ZNF384-r (3, 0.6%) and 165 TCF3::HLF (4, 0.7%) subgroups of B-ALL were exclusively identified using RNA-sequencing 166 (Figure 1). Among the BCR::ABL1-like category, almost equal division was seen among the 167 BCR::ABL1-like: ABL-class (n-11) and JAK-STAT activated (n-13) classes. Among the 168 BCR::ABL1-like: ABL-class, the 3' partner were PDGFRB (EBF1; n=5), ABL1 (n=4; one each 169 of ETV6, NUP214, RANBP2, FOXP1), ABL2 (RCSD1) and CSF1R (LBD1) and those in JAK-170 STAT activated class were CRLF2 (n=9; P2RY8; n=8 and one IGH), JAK2 (n=4; comprising PAX5; n=3 and one EBF1). For PAX5^{alt} category, the 3' fusion partners were AUTS2 (n=5), 171 172 succeeded by MBNL1 (n=3), ETV6 (n=2), IGH (n=2), ZNF521 (n=2) and one each with *CBFA2T3*, *FOXP1*, *GSE1*, *ANKRD12*, *CA10*, and *ESSRB*. For *MEF2D*-r, the fusion partners
were *BCL9* (n=8), *HNRNPUL* (n=3), *DASAP1* (n=1) and *SF1* (n=1). For *ZNF384*-r cases, the
fusion partners were *TCF3* (n=2) and *EP300* (n=1).

Targeted DNA sequencing further helped identify additional *PAX5*^{alt} (n=4) and the *PAX5*P80R group (n=4). Using this approach, we could identify a genomic abnormality in 81.2% of all
cases when compared to legacy approaches (61.7%)

179 Patients harboring BCR::ABL1 (median age- 10 years; p<0.001), BCR::ABL1-like 180 (median age- 11.5 years, p=0.001), and MEF2D-r (median age- 9 years; p=0.004) were 181 significantly older compared to the entire cohort (median age- 5 years; range- 1 to 15 years). BCR::ABL1 (median WBC- 61.7 x 10^{9} /L; p=0.003) and BCR::ABL1 like (median WBC- 33.5 x 182 183 10^{9} /L; p=0.005) showed higher WBC counts as compared to the entire cohort (median WBC- 6.4 x 10^{9} /L; range- 0.2 to 692.3 x 10^{9} /L). Additionally, the *BCR::ABL1* (48.3% MRD-positive; 184 185 median MRD: 0.48; p=0.02) and BCR::ABL1-like (70.8% MRD-positive; median MRD: 1.6; 186 p<0.0001) groups exhibited higher PI MRD positivity as compared to the rest (32.3% PI MRD-187 positive; median PI MRD: 0.14%). The MRD characteristics of each sub-group are detailed in 188 supplementary data and highlighted in Supplementary Figure 3.

IKZF1 deletion was identified in 69 (15.1%) of the 458 patients tested and showed a high
prevalence in the *BCR::ABL1* (56.5%) and *BCR::ABL1*-like (55.6%) genetic subgroups.
Additionally, *IKZF1* deletions were detected across various other subgroups, including NOS,
high hyperdiploidy, *PAX5*^{alt}, *DUX4*-r, *KMT2A*-r, hypodiploidy, *ETV6::RUNX1*, and iAMP21
(Supplementary Figure 4).

194	Re-stratification from the WHO 2016 to WHO 2022 classification: There was no change
195	in the classification of 373 patients (ETV6::RUNX1, High hyperdiploidy, BCR::ABL1,
196	TCF3::PBX1, BCR::ABL1 like KMT2A-r, hypodiploidy, iAMP21) when they were classified as
197	per the WHO 2022 compared to the WHO 2016. Among WHO 2016-defined NOS subgroup
198	(n=160, 30% of the entire cohort), 60 (37.5%) children were reclassified into newly recognized
199	subtypes such as PAX5 ^{alt} (n=24, 15%), DUX4-r (n=12, 7.5%), MEF2D-r (n=13, 8.1%), PAX5
200	P80R (n=4, 2.5%), <i>TCF3::HLF</i> (n=4, 2.5%), and <i>ZNF384-r</i> (n=3, 1.9%) as seen in Figure 1A.

Patient Outcomes: The 2-year EFS and OS of the entire cohort were 75.8% and 85.1%, 201 202 respectively (median EFS and OS not reached). The median follow-up of the cohort was 26.8 203 months. The presence of PI MRD predicted a significantly inferior EFS [HR- 2.0; 95% CI- 1.42] 204 to 2.89; (p<0.0001)] and OS [HR- 1.7; 95% CI- 1.08 to 2.64; (p=0.01)]. Similarly, PC MRD 205 positivity was associated with markedly worse EFS [HR- 22.0; 95% CI- 4.37 to 110.93; 206 (p < 0.0001)] and OS [HR- 2.4; 95% CI- 0.78 to 7.70; (p = 0.02)] (Supplementary Figure 5). The 207 impact of ICiCLe risk stratification on patient outcomes is detailed in the supplementary data 208 (Supplementary Figure 6).

209 Outcomes for individual genetic subgroups: On evaluating the impact of genetic subgroups, the following were associated with inferior EFS: PAX5^{alt} (HR- 2.8; 95% CI- 1.18 to 210 211 6.68; p=0.0001), BCR::ABL1 (HR- 2.5; 95% CI- 1.17 to 5.51; p=0.0002), MEF2D-r (HR- 2.3; 212 95% CI- 0.75 to 7.20; p=0.024), and BCR::ABL1-like with ABL-class fusion (HR-2.3; 95% CI-0.68 to 7.55; p=0.043) (Table 3). Subgroups associated with inferior OS were PAX5^{alt} (HR-4.3: 213 214 95% CI- 1.46 to 12.96; p<0.0001) and BCR::ABL1 (HR-2.4; 95% CI- 0.98 to 6.11; p=0.004). 215 Similarly, IKZF1 deletion was associated with inferior EFS (HR-3.0; 95% CI- 1.72 to 5.07; 216 p<0.0001) and OS (HR-1.8; 95% CI- 0.95 to 3.51; p=0.022). TCF3::HLF subgroup also

exhibited poor EFS, with three out of four affected children having refractory disease and one
experiencing an early relapse; however, statistical analysis was not performed due to the small
sample size.

Conversely, high hyperdiploidy was associated with superior EFS (HR-0.4; 95% CI- 0.26 to 0.49; p < 0.0001) and OS (HR-0.4; 95% CI- 0.29 to 0.65; p=0.0006). *ETV6::RUNX1* also predicted superior EFS (HR-0.4; 95% CI- 0.27 to 0.65; p=0.006) and OS (HR- 0.4; 95% CI- 0.23 to 0.72; p=0.027) as seen in Table 3.

224 *Genetic risk assignment:* We devised a 3-tier genetic risk model (SGR, IGR, and HGR) 225 incorporating variables found to be significantly predictive of EFS on univariate analysis in the 226 present study. Furthermore, if the number of available cases was <10 in our study, available 227 literature for those categories was considered (for, e.g., TCF3::HLF). Genetic categories with a 228 hazard ratio (HR) < 0.75 were classified as SGR, those with an HR between 0.75 and 2 as IGR, 229 and those with an HR > 2 as HGR. The details of this classification can be seen in Figure 3. The 230 2-year EFS for SGR, IGR, and HGR was 92.6%, 71.2%, and 50.3%, respectively (p<0.0001), 231 and the 2-year OS for SGR, IGR, and HGR were 94.3%, 81.9%, and 71.6%, respectively 232 (p<0.0001; Table 4).

Genetic Risk Identifies Heterogeneous Outcomes within ICiCLe Risk Groups: Since patients in this cohort were treated with risk-adapted protocol, we further evaluated the effect of genetic risk stratification in risk groups treated with similar intensities. The ICiCLe initial SR and IR were combined for this analysis, while the HiR group was analyzed separately. Genetic risk stratification retained its prognostic significance within both ICiCLe initial SR/IR and HiR groups. The 2-year EFS of SGR, IGR, and HGR within ICiCLe initial SR/IR were 93.8%,

239	74.0%, and 50.0%, respectively (p<0.0001), and that within ICiCLe initial HiR was 89.2%,
240	64.4% and 51.1% respectively (p<0.0001) (Figure 4). Similarly, the 2-year OS of SGR, IGR, and
241	HGR within ICiCLe initial SR/IR were 94.2%, 81.4%, and 70.6%, respectively (p<0.0001), and
242	that within ICiCLe initial HiR was 94.5%, 83.8% and 73.1% respectively (p=0.026) (Table 4).

243 Genetic Risk Identifies Heterogeneity in Standard Risk B-ALL Irrespective of MRD 244 Status: Patients in the SGR group exhibited superior outcomes regardless of PI MRD status, with 245 2-year EFS rates of 93.9% for MRD-positive and 90.6% for MRD-negative patients (p=0.469), 246 and 2-year OS rates of 95.9% and 93.5%, respectively (p=0.954). In the IGR group, OS was 247 similar between MRD-negative (84.2%) and MRD-positive (79.9%) patients (p=0.239). In the 248 HGR group, OS was 79.6% for MRD-negative and 68.3% for MRD-positive patients (p=0.054). 249 However, MRD status remained a significant predictor of EFS in the IGR and HGR groups, with 250 2-year EFS rates of 58.7% for MRD-positive versus 77.4% for MRD-negative in the IGR group 251 (p=0.017), and 34.2% for MRD-positive versus 67.4% for MRD-negative in the HGR group 252 (p<0.0001) (Table 4, Figure 4).

253 *Multivariate analysis:* On multivariate analysis, genetic risk stratification (HR-2.0; 95% 254 CI- 1.62 to 2.45; p<0.0001), initial ICiCLe risk (HR-1.3; 95% CI- 1.05 to 1.57; p=0.015), and PI 255 MRD (HR-2.0; 95% CI- 1.42 to 2.74; p<0.0001) independently predicted EFS, with genetic risk 256 stratification (HR-1.7; 95% CI- 1.29 to 2.17; p=0.0001) and PI MRD positivity (HR-1.6; 95% 257 CI- 1.03 to 2.38; p<0.0001) also independently impacting OS (Supplementary Table 2).

258 **Discussion:**

259 Pioneering recent studies have utilized unbiased broad-spectrum approaches such as WTS/WGS to uncover novel genetic subtypes^{4,17}, which have been recognized as distinct entities 260 in the latest WHO5/ICC classification of B-ALL.¹⁶ Routine clinical application of WTS/WGS 261 262 assays remains challenging. Herein, we demonstrate that targeted RNA and DNA sequencing, in 263 combination with standard FISH/cytogenetics, is routinely implementable in clinical practice and 264 can detect all of the WHO5-recognized subtypes of B-ALL. We demonstrate that a targeted 265 sequencing approach identifies prognostically relevant subgroups even in the era of 266 contemporary MRD-directed therapies.

Among the recently defined genetic categories, we found frequencies of 4.5% for 267 BCR::ABL1-like, 4.5% for PAX5^{alt}, 2.44% for MEF2D-r, 2.25% for DUX4-r, and 0.75% each for 268 PAX5 P80R, and TCF3::HLF, and 0.56% for ZNF384-r. The proportion of PAX5^{alt} (4.5% vs. 269 $(7.5\%)^4$, and DUX4-r $(2.25\% \text{ vs. } 4\%)^3$ cases in our cohort are lower than that reported in the 270 271 discovery cohorts. The NARASIMHA assay used in this study focuses only on detecting chimeric gene fusions. Unbiased sequencing approaches such as WTS that include gene 272 273 expression profiling might have uncovered further cases of BCR::ABL1-like and DUX4-r. 274 Additionally, we could not detect other specific categories, such as ETV6::RUNX1-like, due to a 275 lack of gene expression profiling. Another factor to consider is that we report results only on a 276 large cohort of children uniformly recruited in the ICiCLe-ALL-14 trial. Interestingly, 277 transcriptomic sequencing findings from the St. Jude Total Therapy Study 16 trial reported similar BCR::ABL1-like (3%) and PAX5^{alt} (4.85%) cases.⁷ In total, 81.2% of the children 278 279 analyzed could be assigned to a defined genetic subgroup using our approach of targeted 280 RNA/DNA sequencing. In comparison, 18.7% of cases remained uncharacterized (B other) in

contrast to 12.1% B-other cases reported in the St. Jude Total Therapy Study 16.⁷ While this gap
highlights the need for broader spectrum genomic profiling in future studies, our approach
provides a viable framework that detects most of the WHO5-recognised genetic abnormalities in
children with B-ALL in a trial setting.

285 Here, we developed a three-tier genetic risk model incorporating variables predictive of 286 EFS in a large cohort of children treated uniformly with MRD-directed risk-adapted ICiCLe-287 ALL-14 protocol. In addition to the high hyperdiploidy and ETV6::RUNX1, the SGR group also 288 included DUX4-r. Children with DUX4-r had a 2-year EFS of 73.3 months (HR- 0.73; 95% CI-289 0.27 to 1.94) in our cohort, and although the presence of DUX4-r was not associated with 290 statistically significant better EFS, possibly due to only 12 cases, DUX4-r has been reported to be associated with superior outcome in earlier reports.⁷ KMT2A-r are often linked with adverse 291 292 outcomes in both infants and adults with B-ALL. Our study included a cohort of 1-15-year-olds, and similar to the study where non-infant children with KMT2A-r were evaluated,¹⁸ our cohort of 293 294 KMT2A-r B-ALL demonstrated an intermediate 2-year EFS of 67.5%, thus being grouped into 295 IGR. Interestingly, only the BCR::ABL1-like with ABL class-r was associated with inferior 296 outcome (median EFS 31.3 months; HR-2.3; 95% CI- 0.68 to 7.55; p=0.043) in our cohort and 297 included in HGR, while the JAK-STAT perturbed BCR::ABL1-like group (median not reached; 298 HR- 1.00; 95% CI- 0.37 to 2.65; p=0.98) was not associated with significant outcome difference 299 and was included in the IGR category. Although BCR::ABL1-like B-ALL is generally associated 300 with inferior prognosis irrespective of age, previous reports have suggested that MRD-directed therapy may be beneficial in abrogating the prognostic impact.¹⁹ In a retrospective multi-centric 301 302 study of the pre-tyrosine kinase inhibitor (TKI) era, BCR::ABL1-like ABL-class-r had inferior outcomes.²⁰ Our cohort of BCR::ABL1-like B-ALL has a relatively larger proportion of ABL-303

304 class-r cases, which might have allowed the identification of distinct inferior outcomes of this 305 subgroup. Among the patients of BCR::ABL1-like ABL-class-r, nine received TKI, despite which their outcome remained poor. The PAX5^{alt} group had the worst 2-year EFS (39.1%, HR-306 307 2.8; 95% CI- 1.18 to 6.68, p=0.0001) in our cohort and is included in the HiR category. Initial studies from the SJRCH/COG group have reported an intermediate prognosis of PAX5^{alt} with 308 MRD-directed therapy,^{4,7} however, based on the dismal EFS in our cohort, we have included the 309 PAX5^{alt} in the HGR category. This finding aligns with the recently published study by Chang 310 and colleagues, where approximately 50% of children with PAX5^{alt} ALL relapsed, highlighting 311 the poor prognosis of this subtype in standard-risk pediatric patients.²¹ We included *IKZF1* 312 313 deletion, *MEF2D*-r and *TCF3::HLF* in the HGR category, which is in line with previous findings by the SJRCH/COG group.^{4,7} 314

315 The genetic risk groups proposed here were associated with distinct EFS across ICiCLe 316 risk groups and had an independent association with EFS on multivariate analysis, in addition to 317 ICiCLe-ALL-14 initial risk and PI MRD status. On combining genomic data with PI MRD 318 assessments, we found out that the SGR group was associated with uniformly superior prognosis 319 irrespective of MRD status. This, however, should not be interpreted as a rationale to deescalate therapy as the patients with MRD positive in the SGR category were all treated with high-risk 320 321 consolidation in this cohort. MRD positive status was associated with inferior outcomes within 322 the IGR and HGR categories, suggesting that a combination of genomic risk group and MRD 323 status might form the most optimum strategy for risk-adapted protocols in children with B-ALL.

We acknowledge the limitation of our study of relatively shorter follow-up and lack of gene expression profiling. Incorporating unbiased sequencing approaches will help further delineate the genetic makeup of the NOS cases and may identify missed cases. However, the

 329 MRD status, may help in refining risk-stratification approaches in children with B-ALL. 330 In conclusion, we demonstrate the applicability of the WHO5 classification in refining risk-stratification. 	327	stepwise approach, targeted RNA/DNA sequencing strategy, and the genomic risk score
330 In conclusion, we demonstrate the applicability of the WHO5 classification in r	328	described in this manuscript are easily implementable in routine practice and, together with
	329	MRD status, may help in refining risk-stratification approaches in children with B-ALL.
331 practice and create a general framework for the incorporation of the WHO5 classification in	330	In conclusion, we demonstrate the applicability of the WHO5 classification in routine
	331	practice and create a general framework for the incorporation of the WHO5 classification in risk-

adapted therapy for childhood B-ALL.

333 Acknowledgements:

We would like to express our sincere gratitude to Rakhi Salve, Bhagyashree Satam, Tuhina Srivastava, Harsh Chindarkar and Dr. Shivangi Harankhedkar for their invaluable assistance in entering and managing the patient data for this study. Their contributions were crucial to the successful completion of this work. We also acknowledge Mr Sitaram Ghogale and Mr Nilesh Deshpande for processing samples for flow cytometry testing.

339

340 Authorship and conflict-of-interest statements:

SR, NP and GC designed the study, conducted research, analyzed, interpreted the data, and wrote the manuscript. PB, SJ, SC, PT, DS, SG and PS conducted research conducted research and analyzed data. SS, AC, CD, NM, SB and GN recruited patients and analyzed data. Dr Nikhil Patkar is supported by an India Alliance (Wellcome-DBT) Senior Fellowship for Clinicians and Public Health Researchers. Dr Gaurav Chatterjee is supported by an India Alliance (Wellcome-DBT) Intermediate Fellowship for Clinicians and Public Health Researchers. Dr Nikhil Patkar has received research funding from Illumina Inc and ThermoFisher Scientific.

349

348

350 Agreement to Share Publication-Related Data and Data Sharing Statement:

The author(s) declare no competing financial interests.

351 Dr Nikhil Patkar, Department of Haematopathology, CCE Building, Advanced Centre for
352 Treatment Research and Education in Cancer, Tata Memorial Centre, Kharghar, Maharashtra,
353 India, Pin:410210. Email: nvpatkar@gmail.com; npatkar@actrec.gov.in. Phone: +91-22354 27405000

Demographics	
Total number of patients accrued	533
Age (years)	Range:- 1-15, Median:- 5
Gender	Male: Female- 1.99:1
Laboratory characteristics	
TLC at presentation	
1. $\geq 50 \ge 10^{\circ}/L$	81 (15.2%)
2. <50 x 10 [°] /L	452 (84.8%)
WHO 2016 Genetic categories	
1. Hyperdiploidy	182 (34.1%)
2. ETV6::RUNX1	68 (12.8%)
3. TCF3::PBX1	42 (7.9%)
4. BCR::ABL1	29 (5.4%)
5. BCR::ABL1 like	24 (4.5%)
6. KMT2A rearranged	19 (3.6%)
7. Hypodiploidy	6 (1.1%)
8. iAMP21	3 (0.6%)
9. NOS	160 (30.0%)
NCI Risk	
SR	358 (67.2%)
HR	175 (32.8%)
ICiCLe Initial Risk (n-533)	
SR	205 (38.4%)
IR	148 (27.8%)
HR	180 (33.8%)
ICiCLe Risk (n-519)	
SR	119 (22.9%)
IR	102 (19.7%)
HR	298 (57.4%)
Post-induction MRD (n=519)	
Positive	167 (32.2%), Median- 0.14, Range- 0.01-88
Negative	352 (67.8%)
Post-consolidation MRD (n=244)	
Positive	24 (9.8%), Median- 0.2, Range- 0.01-86
Negative	220 (90.2%)

359 Table 1. Demographic and Laboratory Characteristics, WHO 2016 Classification, MRD

360 characteristics and Risk Stratification of B-ALL Patients

361

Genetic category	N (%)	Median age in years (range), p- value*	Male n (%), p-value*	Median WBC (range) at diagnosis (X 10 ⁹ /L) , p-value*	Percentage of PI MRD positive cases (median, range), p- value*
All categories	533	5 (1-15)	355 (66.5)	6.37 (0.23-692.3)	32.2 (0.14, 0.01- 88)
High hyperdiploidy	182 (34.1)	4 (1 – 13), < 0.001	125 (67.2), 1.000	4.63 (0.61–253.0), < 0.001	30.3 (0.01, 0.01- 11), 0.38
ETV6::RUNX1	68 (12.8)	4 (1 – 15), 0.003	44 (66.7), 1.000	4.85 (0.23–90.1), 0.064	24.2 (0.02, 0.01-5.8), 0.10
TCF3::PBX1	42 (7.9)	6(2-14), 0.154	24 (57.1), 0.177	14.185 (1.22–281.0) , 0.003	26.2 (0.03, 0.01-3.60), 0.55
BCR::ABL1	29 (5.4)	10 (2 – 14), <0.001	22 (75.9), 0.318	61.71 (1.11–559.4), <0.01	48.3 (0.48, 0.01-23.50) , 0.01
<i>BCR::ABL1</i> like	24 (4.5)	11.5 (3-15), 0.001	17 (70.8), 0.825	33.525 (0.93–295.1) , 0.005	70.8 (1.6, 0.01-62), 0.000033
PAX ^{alt}	24 (4.5)	4 (1-14), 0.354	16 (69.6), 0.825	8.15 (0.59–208.5), 0.637	23.8 (0.04, 0.01-1.1), 0.46
KMT2A-r	19 (3.6)	3 (0-14), 0.001	12 (63.2), 0.806	19.54 (1.37–424.71) , 0.055	26.3 (0.26, 0.01-50), 0.76
MEF2D-r	13 (2.4)	9 (3-14), 0.004	5 (38.5), 0.038	11.15 (1.31–119.11) , 0.252	30.8 (0.05, 0.01- 0.24), 1.00
DUX4-r	12 (2.3)	6 (3-14), 0.167	9 (75.0), 0.759	5.14 (1.56–27.73), 0.358	33.3 (0.03, 0.01-3.5), 1.00
Hypodiploidy	6 (1.1)	11 (4-13)	4 (66.7)	3.27 (1.34–155.1)	33.3 (0.01, 0.01-4.3)
PAX5 P80R	4 (0.7)	12 (8-14)	4 (100)	55.87 (1.99-86.8)	0
TCF3::HLF	4 (0.7)	8 (4-14)	3 (75)	6.335 (1.32–9.74)	75.0 (1.25, 0.01- 6.5)
ZNF384-r	3 (0.6)	5 (4-16)	1 (33.3)	14.33 (4.37–22.32)	66.7 (6.20, 0.32- 12.09)
iAMP21	3 (0.6)	6 (2-10)	2 (66.7)	3.04 (2.94-5.4)	0, 0.56
NOS	100 (18.8)	7 (1 – 14), < 0.001	70 (70.0), 0.481	8.07 (0.29-692.3), 0.147	33.0 (0.05, 0.01-71.7), 1.00

362 Table 2. Age and Sex Distribution, WBC Counts, and MRD characteristics across Genetic

Subgroups. *p-values are not provided for genetic subgroups with fewer than 10 cases.

	Overall survival				Event free survival			
	2 years OS	P-value	Hazard ratio (95% Confidence Interval)	2 years EFS	P-value	Hazard ratio (95% Confidence Interval)		
IKZF1 del	77.5	0.022	1.8 (0.95 to 3.51)	46.2	< 0.0001	3.0 (1.72 to 5.07)		
PAX5 ^{alt}	46.6	< 0.0001	4.3 (1.46 to 12.96)	39.1	0.0001	2.8 (1.18 to 6.68)		
BCR::ABL1	67.6	0.004	2.4 (0.98 to 6.11)	50.6	0.0002	2.5 (1.17 to 5.51)		
MEF2D-r	66.1	0.114	2.2 (0.51 to 9.33)	53.8	0.024	2.3 (0.75 to 7.20)		
<i>BCR::ABL1</i> like, ABL-Class	90.9	0.821	0.9 (0.23 to 3.11)	60.6	0.043	2.3 (0.68 to 7.55)		
NOS	84.2	0.714	1.1 (0.67 to 1.79)	65.9	0.015	1.6 (1.03 to 2.33)		
TCF3::PBX1	77.3	0.133	1.6 (0.77 to 3.26)	67.4	0.253	1.3 (0.76 to 2.36)		
Hypodiploidy	83.3	0.961	1.1 (0.14 to 7.90)	66.7	0.684	1.3 (0.27 to 6.64)		
KMT2A-r	72.0	0.214	1.8 (0.5469 to 5.6249)	67.5	0.645	1.2 (0.50 to 2.95)		
<i>BCR::ABL1</i> like, JAK-STAT	84.6	0.730	1.2 (0.35 to 4.33)	63.5	0.98	1.0 (0.37 to 2.65)		
DUX4-r	82.5	0.791	0.8 (0.23 to 2.97)	73.3	0.58	0.7 (0.27 to 1.94)		
ETV6::RUNX1	100	0.027	0.4 (0.23 to 0.72)	98.0	0.006	0.4 (0.27 to 0.65)		
High Hyperdiploidy	92.1	0.0006	0.4 (0.29 to 0.65)	88.9	< 0.0001	0.4 (0.26 to 0.49)		

 Table 3. Event-free and overall survival rates for genetic categories of B-ALL, as classified by

 WHO 2022, including hazard ratios and p-values. The genetic categories with fewer than 10 cases

 are not included in the table.

	Impact of Ge	netic Risk o	on Patient Ou	atcomes (n-53	3)	
	-	nt free surv			erall surviv	al
	Hazard ratio (95%	2 year EFS	p-value	Hazard ratio (95%	2 year EFS	p-value
	confidence interval)			confidence interval)		
Standard genomic risk (SGR)	1	92.6%	<0.0001	1	94.3%	< 0.0001
Intermediate	2.77 (1.91	71.2%		2.37 (1.48	81.9%	
genomic risk (IGR) High genomic risk	to 4.02) 5.34 (3.61	50.3%		to 3.79) 3.81 (2.34	71.6%	_
(IGR)	to 7.89)			to 6.19)		
Survival analyses i						
		nt free survi	1		erall surviv	1
	Hazard	2 year	p-value	Hazard	2 year	p-value
	ratio (95%	EFS		ratio (95%	EFS	
	confidence interval)			confidence interval)		
ICiCLe SR/IR & SGR	1	93.8%	<0.0001	1	94.2%	< 0.0001
ICiCLe SR/IR & IGR	2.81 (1.76 to 4.48)	74.0%		2.34 (1.34 to 4.08)	81.4%	
ICiCLe SR/IR &	5.70 (3.18	50.0%		4.38 (2.21	70.6%	-
HGR	to 10.20)	1	· ta:at	to 8.68)	•	(101)
Survival analyses in genetic risk categories in ICiCLe initial HiR risk categories (n-181)						
		nt free survi			erall surviv	
	Hazard ratio (95% confidence	2 year EFS	p-value	Hazard ratio (95% confidence	2 year EFS	p-value
	interval)			interval)		
ICiCLe HiR & SGR	1	89.0%	< 0.0001	1	94.5%	0.026
ICiCLe HiR & IGR	2.67 (1.39 to 5.10)	64.4%		2.35 (0.96 to 5.74)	83.8%	
ICiCLe HiR &	4.36 (2.53	51.1%		3.28 (1.55	73.1%	-
HGR	to 7.51)		1 1	to 6.93)	2)	
Impact of PI MRD in standard genomic risk (n-248)						
	Hazard	nt free survi 2 year	p-value	Ov Hazard	erall surviv 2 year	p-value
	ratio (95% confidence	EFS		ratio (95% confidence	EFS	•
SGR with PI MRD Negative	interval) 1	93.9%	0.47	interval) 1	95.9%	0.96

SGR with PI MRD	0.75 (0.36	90.6%		1.02 (0.42	91.7%			
positive	to 2.80)			to 2.48)				
Ir	npact of PI M	RD in inter	mediate gen	omic risk (n-1	30)			
	Ever	nt free survi	ival	Ov	erall surviv	al		
	Hazard	2 year	p-value	Hazard	2 year	p-value		
	ratio (95%	EFS		ratio (95%	EFS			
	confidence			confidence				
	interval)			interval)				
IGR with PI MRD	1	77.4%	0.017	1	82.8%	0.239		
Negative								
IGR with PI MRD	2.03 (1.03	58.7%		1.56 (0.69	79.9%			
positive	to 4.00)			to 3.50)				
Impact of PI MRD in high genomic risk (n-141)								
	Event free survival			Ov	erall surviv	al		
	Hazard	2 year	p-value	Hazard	2 year	p-value		
	ratio (95%	EFS		ratio (95%	EFS			
	confidence			confidence				
	interval)			interval)				
HGR with PI MRD	1	67.4%	< 0.0001	1	79.6%	0.054		
Negative								
HGR with PI MRD	2.71 (1.65	34.2%		1.86 (0.97	68.3%			
positive	to 4.43)			to 3.55)				

370

371 Table 4. Genetic risk-based survival outcomes and the impact of post-induction measurable

372 residual disease positivity.

373

375 **References**

- Moorman A V., Enshaei A, Murdy D, Joy M, Boer JM, den Boer ML *et al.* Integration of
 genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic
 leukaemia with intermediate MRD levels at the end of induction. *Leukemia* 2024; 38.
 doi:10.1038/S41375-024-02329-0.
- Moorman A V., Enshaei A, Schwab C, Wade R, Chilton L, Elliott A *et al.* A novel
 integrated cytogenetic and genomic classification refines risk stratification in pediatric
 acute lymphoblastic leukemia. *Blood* 2014; **124**: 1434–1444.
- 383 3 Lilljebjörn H, Henningsson R, Hyrenius-Wittsten A, Olsson L, Orsmark-Pietras C, Von
 384 Palffy S *et al.* Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in
 385 paediatric B-cell precursor acute lymphoblastic leukaemia. *Nat Commun* 2016; **7**.
 386 doi:10.1038/NCOMMS11790.
- Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J *et al.* PAX5-driven
 Subtypes of B-progenitor Acute Lymphoblastic Leukemia. *Nat Genet* 2019; **51**: 296.
- Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E *et al.* The
 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:
 Lymphoid Neoplasms. Leukemia. 2022; **36**. doi:10.1038/s41375-022-01620-2.
- 3926Duffield AS, Mullighan CG, Borowitz MJ. International Consensus Classification of acute393lymphoblastic leukemia/lymphoma. Virchows Arch 2023; 482: 11–26.
- Jeha S, Choi J, Roberts KG, Pei D, Coustan-Smith E, Inaba H *et al.* Clinical Significance
 of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual
 Disease–Directed Therapy. *Blood Cancer Discov* 2021; **2**: 326–337.
- Tanasi I, Ba I, Sirvent N, Braun T, Cuccuini W, Ballerini P *et al.* Efficacy of tyrosine kinase
 inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. *Blood* 2019; **134**: 1351–1355.
- Gudapati P, Khanka T, Chatterjee G, Ghogale S, Badrinath Y, Deshpande N *et al.*CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual
 disease assessment of B-cell precursor acute lymphoblastic leukemia. *Cytometry B Clin Cytom* 2020; **98**: 328–335.
- Tembhare P, Badrinath Y, Ghogale S, Patkar N, Dhole N, Dalavi P *et al.* A novel and
 easy FxCycle[™] violet based flow cytometric method for simultaneous assessment of
 DNA ploidy and six-color immunophenotyping. *Cytometry Part A* 2016; **89**: 281–291.
- 407 11 Amare PSK, Jain H, Kabre S, Deshpande Y, Pawar P, Banavali S *et al.* Cytogenetic
 408 Profile in 7209 Indian Patients with <i>de novo</i> Acute Leukemia: A Single
 409 Centre Study from India. *J Cancer Ther* 2016; **07**: 530–544.
- 410 12 van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G *et al.*411 Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations
 412 in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1
 413 Concerted Action: investigation of minimal residual disease in acute leukemia. *Leukemia*414 1999; **13**: 1901–28.
- Caye A, Beldjord K, Mass-Malo K, Drunat S, Soulier J, Gandemer V *et al.* Breakpoint specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic

leukemia. Haematologica 2013; 98: 597-601.

deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic


417

418

419	14	Das N, Banavali S, Bakhshi S, Trehan A, Radhakrishnan V, Seth R et al. Protocol for
420		ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised,
421		multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute
422		lymphoblastic leukaemia in India. <i>Trials</i> 2022; 23 : 1–20.
423	15	Tembhare PR, Subramanian PG PG, Ghogale S, Chatterjee G, Patkar N V., Gupta A et
424		al. A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-
425		Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-106 and Is
426		Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients.
427		Cytometry B Clin Cytom 2020; 98 : 57–67.
428	16	Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E et al. The
429		5th edition of the World Health Organization Classification of Haematolymphoid Tumours:
430		Lymphoid Neoplasms. <i>Leukemia</i> 2022; 36 : 1720–1748.
431	17	Li JF, Dai YT, Lilljebjörn H, Shen SH, Cui BW, Bai L et al. Transcriptional landscape of B
432		cell precursor acute lymphoblastic leukemia based on an international study of 1,223
433		cases. Proc Natl Acad Sci U S A 2018; 115 : E11711–E11720.
434	18	Attarbaschi A, Möricke A, Harrison CJ, Mann G, Baruchel A, De Moerloose B et al.
435		Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/ KMT2A
436		Rearrangements in a Modern Therapy Era: A Retrospective International Study. J Clin
437		Oncol 2023; 41 : 1404–1422.
438	19	Roberts KG, Pei D, Campana D, Payne-Turner D, Li Y, Cheng C et al. Outcomes of
439		children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed
440		therapy based on the levels of minimal residual disease. J Clin Oncol 2014; 32: 3012-
441		3020.
442	20	den Boer ML, Cario G, Moorman A V., Boer JM, de Groot-Kruseman HA, Fiocco M <i>et al.</i>
443		Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class
444		fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.
445		Lancet Haematol 2021; 8 : e55–e66.
446	21	Chang TC, Chen W, Qu C, Cheng Z, Hedges D, Elsayed A et al. Genomic Determinants
447		of Outcome in Acute Lymphoblastic Leukemia. <i>J Clin Oncol</i> 2024.
448		doi:10.1200/JCO.23.02238.
449		

450 Figure Legend


- Figure 1. (a) Sankey Diagram Illustrating the Reclassification of B-ALL Cases from WHO 2016
 to WHO 2022 B-ALL Classification (b) Circos diagram showing fusions identified in pediatric
 B-ALL.
- 454 Figure 2. Event-free survival (EFS) of pediatric B-cell acute lymphoblastic leukemia (B-ALL)
 455 patients (n=533) categorized by genetic subtypes.
- 456 Figure 3. Event-free and overall survival of pediatric B-ALL patients stratified by genetic risk
- 457 classification into standard (SGR), intermediate (IGR), and high (HGR) genetic risk groups.
- 458 Figure 4. (a) Event free survival in pediatric B-ALL stratified by genetic risk and post-induction
- 459 MRD revealing similar outcome in the standard genomic risk category irrespective of post-
- 460 induction measurable residual disease status; (b) Event free survival in pediatric B-ALL stratified
- 461 by ICiCLe initial risk stratification and genetic risk heterogenous outcomes within the ICiCLe
- 462 risk groups.




WHO 2016	WHO 2022
BCR::ABL1	BCR::ABL1
BCR::ABL1 like	BCR::ABL1 like
ETV6::RUNX1	ETV6::RUNX1
—•Hypodiploidy— KMT2A-r	Hypodiploidy KMT2A-r
NOS	NOS
	PAX5alt
	DUX4=r MEF2D-r
	PAX5 P80R TCF3::HLF ZNF384-r
TCF3::PBX1	TCF3::PBX1
hyperdiploidy	high hyperdiploidy

В

-iAMP21-





Standard Genetic Risk (SGR) High hyperdiploidy *ETV6::RUNX1 DUX4-*r Intermediate Genetic Risk (IGR) TCF3::PBX1 KMT2A-r BCR::ABL1 like: JAK-STAT-r PAX5 P80R ZNF384-r NOS High Genetic Risk (HGR) PAX5^{alt} MEF2D-r BCR::ABL1 like: ABL class-r TCF3::HLF BCR::ABL1 Hypodiploidy iAMP21 IKZF1 deletion

